OncoMatch/Clinical Trials/NCT05789589
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Is NCT05789589 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Azeliragon and Corticosteroid for cancer.
Treatment: Azeliragon · Corticosteroid — To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains controlled).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
KARNOFSKY OR ECOG 50–3
Karnofsky performance status ≥ 50 or Eastern Cooperative Oncology Group (ECOG) ≤ 3
Lab requirements
Blood counts
ANC ≥ 1.0 × 10^9/L; Platelet count ≥ 75,000/mm^3; Hemoglobin (Hgb) ≥ 9 g/dL without transfusion or growth factor support
Kidney function
Estimated creatinine clearance of > 60 mL/min (per Cockcroft-Gault formula)
Liver function
AST/ALT ≤ 2.5 × ULN; Total bilirubin ≤ 1.5 × ULN
Absolute neutrophil count (ANC) ≥ 1.0 × 10^9/L; Platelet count ≥ 75,000/mm^3; Hemoglobin (Hgb) ≥ 9 g/dL without transfusion or growth factor support; AST/ALT ≤ 2.5 × ULN; Total bilirubin ≤ 1.5 × ULN; Estimated creatinine clearance of > 60 mL/min (per Cockcroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Miami Cancer Institute at Baptist Health, Inc. · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify